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TNF-αIn dystrophin-deﬁcient ﬁbers ofmdxmice and in Duchenne muscular dystrophy, inﬂammation and increased
production of tumor necrosis factor alpha (TNF-α) contribute to myonecrosis. We examined the effects of
eicosapentaenoic acid (EPA) on dystrophic muscle degeneration. Mdx mice (14 days old) received EPA for
16 days. The sternomastoid, diaphragm and biceps brachii muscles were removed. Controlmdxmice received
vehicle. EPA decreased creatine kinase and myonecrosis and reduced the levels of TNF-α. These results
suggest that EPA plays a protective role in dystrophic muscle degeneration, possibly by reducing TNF-α, and
support further investigations of EPA as a potential therapy for dystrophinopathies.).
vier OA license.© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The absence of dystrophin in Duchenne muscular dystrophy
(DMD) and in the mdx mouse model of DMD is associated with
sarcolemma instability and elevated levels of calcium inmuscle ﬁbers,
factors that lead to myonecrosis. Muscle ﬁber damage activates an
inﬂammatory response that seems to play a central role in the
progression of myonecrosis (Tidball, 2005). Mast cells accumulate
rapidly in response to muscle injury, followed by neutrophils and
macrophages (Radley and Grounds, 2006). Progressive myonecrosis
ultimately results in the replacement of muscle ﬁbers with fat and
ﬁbrosis which, in turn, cause cardiorespiratory failure in dystrophic
patients (Engel et al., 1994).
The proinﬂammatory cytokine tumor necrosis factor alpha (TNF-α),
which is produced by inﬂammatory andmuscle cells (Vassalli, 1992), is
of particular importance for dystrophic ﬁber necrosis. TNF-α is found to
be elevated in DMD and in mdx muscles (Kuru et al., 2003; Grounds
et al., 2008) and higher serum levels are observed in DMD patients
compared to healthy subjects (Saito et al., 2000). In addition, drug
therapydesigned to reduce inﬂammatory cells (Hodgetts et al., 2006), to
blockmast cell degranulation (Radley andGrounds, 2006) and to inhibit
TNF-α and TNF-signaling mechanisms (Waters et al., 2010) has been
shown to ameliorate dystrophy and demonstrates the role of inﬂam-
mation and TNF-α in the progression of dystrophy.The omega-3 fatty acid, eicosapentaenoic acid (EPA), has anti-
inﬂammatory properties and several clinical trials have reported
potential health beneﬁts of omega-3 polyunsaturated fatty acids in
many diseases, including cardiovascular diseases (Harper et al., 2006),
epilepsy (Schlanger et al., 2002), inﬂammatory bowel disease (Calder,
2008), post-operative trauma (Roulet et al., 1997), exercise-trained
subjects (Bloomer et al., 2009), and cancer-associated cachexia (Babcock
et al., 2000). EPA has also been shown to inhibit the proinﬂammatory
transcription factor nuclear factor kappa B (NF-kB) (Babcock et al., 2000;
Singer et al., 2008), to reduce TNF-α production by macrophages
(Babcock et al., 2002) and to prevent the damaging effects of TNF-α
during skeletal muscle differentiation in vitro (Magee et al., 2008).
There is currently no effective therapy for DMD. Corticosteroids are
the main drugs of choice despite their side effects (Bonifati et al., 2000;
Moxley et al., 2005) and long-term treatment is necessary. Despite
advances in genetic and cell-based therapies (Tremblay et al., 2009;
Heemskerk et al., 2010), the search for new drugs or nutritional
interventions for DMD is relevant (Payne et al., 2006; Radley et al.,
2007). In view of the anti-inﬂammatory and anti-TNF-α properties of
EPA,we hypothesized that this agentwould protect dystrophin-deﬁcient
mdxmuscle ﬁbers against degeneration.
2. Materials and methods
2.1. Animals
Male and female mdx mice (C57BL/10-Dmdmdx/PasUnib) obtained
from a breeding colony maintained by our institutional animal care
146 R.V. Machado et al. / Journal of Neuroimmunology 232 (2011) 145–150facility were used in all experiments. Some C57BL/10 mice (C57BL/
10ScCr/PasUnib) were used for focused experiments. The mice were
housed according to institutional guidelines, with free access to food
and water. Pregnant females were isolated and monitored daily. The
date of birth was designated postnatal day 0. EPA treatment was
initiated on postnatal day 14 before the cycles of muscle degenera-
tion–regeneration had started (Cullen and Jaros, 1988). Mice were
weaned at 4 weeks of age. The animal experiments described here
were done in accordance with the guidelines of the Brazilian College
for Animal Experimentation (COBEA; protocol # 2165-1) and the
guidelines set forth by our Institution.
2.2. Drug administration
EPA-treated mdx mice (n=15) received EPA (cis-5,8,11,14,17-
Eicosapentaenoic acid, 98.5% of EPA in composition, oil density
0.943 g/ml, Fluka/Sigma-Aldrich®, St. Louis, MO, USA) daily, by
gavage, at a dose of 300 mg/kg body weight (Matsumoto et al.,
2009) in 100% mineral oil (Nujol, liquid petrolatum for oral human
use, Mantecorp, SP, Brazil) for 16 days. Eachmouse was weighed daily
so that the drug dosage could be adjusted accurately. The amount of
oil received was 0.01 ml/gavage. Control litter mdx mice (n=15;
untreated) received an equivalent amount of mineral oil.
2.3. Evans blue dye analysis
For visualization of muscle ﬁber leakiness/necrosis, treated and
untreated-mdx mice were injected with Evans blue dye (EBD;
Sigma®, St. Louis, MO, USA); (Matsuda et al., 1995). EBD was
dissolved in phosphate-buffered saline (PBS; 0.15 M NaCl, 10 mM
phosphate buffer, pH 7.4) and injected into the peritoneal cavity. The
animals (5 EPA-treated and 5 untreated) received an intraperitoneal
injection of 1% EBD in PBS at a dose of 100 μl per 10 g of body weight.
The mice were visually inspected for dye uptake. Discoloration of all
mice was observedwithin 50–60 min after intraperitoneal injection of
EBD, and successful injection of the dye was indicated by the blue
color of the ears and paws.
Twenty-four hours later, the mice were anesthetized with a
mixture of ketamine hydrochloride (130 mg/kg, Francotar, Virbac, São
Paulo, Brazil) and xylazine hydrochloride (6.8 mg/kg, 2% Virbaxyl,
Virbac, São Paulo, Brazil). The sternomastoid (STN), diaphragm (DIA),
and biceps braquii (BB)muscles were dissected out and snap frozen in
isopentane cooled in liquid nitrogen and stored at −80 °C. These
muscles were chosen because they are differently affected, with the
diaphragm being more severely impaired than other muscles in the
later stages of the disease (Stedman et al., 1991).
Cryostat cross-sections (7 μm thick) were incubated in ice-cold
acetone at −20 °C for 10 min, washed three times for 10 min with
PBS, and mounted in DABCO (mounting medium for ﬂuorescence
microscopy; Sigma). EBD staining shows a bright red emission upon
ﬂuorescence microscopy. Fiber counts of EBD-positive muscle ﬁbers
were performedwith a hand counter in all sections and photographed
under a Nikon ﬂuorescence microscope connected to a Hamamatsu
video camera. The number of EBD-positive muscle ﬁbers is expressed
as the percentage of the total number of muscle ﬁbers counted in each
section (4–5 sections for each muscle).
2.4. Quantitative and morphometric analysis
Cryostat cross-sections of STN, DIA and BB from EPA-treated
(n=7) and untreated (n=7) were stained with hematoxilin–eosin
(HE). Slides were placed in a Nikon Eclipse E 400 microscope
connected to a personal computer and attached to a video camera
(Nikon Express Series; Tokyo, Japan). Non-overlapping images of the
entire cross-section were taken and tiled together using the
ImagePro-Express software (Media Cybernetic; Silver Spring, MD).For each cross-section (4–5 sections for each muscle), the numbers of
central nucleated ﬁbers and ﬁbers with peripheral nuclei were
counted using a hand counter and expressed as the percentage of
the total number of ﬁbers.
Areas with inﬂammatory cell inﬁltrate were characterized and
quantiﬁed as previously described (Marques et al., 2008). In short,
inﬂammatory cells were identiﬁed in hematoxilin–eosin sections
based on nucleus morphology and cell size, showing basophilic
nuclear staining and little cytoplasm. Areas containing inﬂammatory
cells densely packed were measured with the ImagePro-Express
software and were calculated as a percentage of the total muscle area
in each section studied (4–5 sections from each muscle) using the
microscope (Nikon Eclipse E400) ﬁtted with a graduated eyepiece
micrometer at 200× magniﬁcation. Some sections were labeled with
antibody to F4/80 (Serotec; 1:250 dilution in 0.1 M PBS, pH 7.8, and
BSA 1%), a pan macrophage marker (Villalta et al., 2009), followed by
secondary antibody (CY-3; Jackson ImmunoResearch; 1:250 dilution
in 0.1 M PBS, pH 7.8, and BSA 1%). Control mounts for the primary
antibody were incubated with CY-3 anti-rat IgG in blocking solution
instead of the primary antibody. No stained structures were seen in
these controls. All the counting and measurements (EBD, central and
peripheral nucleated cells and inﬂammation area) were done by a
blinded observer.
2.5. Analysis of creatine kinase
For biochemical evaluation of muscle ﬁber damage, EPA-treated
(n=8) and untreated (n=8) mdx mice were anesthetized with a
mixture of ketamine hydrochloride (130 mg/kg, Francotar, Virbac, São
Paulo, Brazil) and xylazine hydrochloride (6.8 mg/kg, 2% Virbaxyl,
Virbac, São Paulo, Brazil). Blood samples (0.8 ml) were collected by
cardiac puncture. After incubation at room temperature for 1–2 h to
allow clotting, the samples were microcentrifuged at 936 g for 10 min,
and the supernatant (serum) was removed and used for analysis. The
creatine kinase (CK) assay was performed using a commercially
available kit (CK Cinético Crystal, Bioclin, Quibasa, Minas Gerais, Brazil)
and a Thermo Electron Corporation Genesys 20 spectrophotometer
(Krackeler Scientiﬁc, Albany, New York, USA). Values are reported as
international units (U/L).
2.6. Western blot analysis
TNF-α was quantiﬁed by western blotting in control C57BL/10
mice (n=8), and in EPA-treated (n=8) and untreated (n=8) mdx
mice. The method employed was described in Ferretti et al. (2009).
Brieﬂy, muscles were lysed in assay lysis buffer (1% Triton, 10 mM
sodiumpyrophosphate, 100 mMNaF, 10 μg/ml aprotinin, 1 mMPMSF,
and 0.25 mM Na3VO4), centrifuged and the soluble fraction was
resuspended in 50 μl Laemmli loading buffer (2% SDS, 20% glycerol,
0.04 mg/ml bromophenol blue, 0.12 M Tris–HCl, pH 6.8, and 0.28 M
ß-mercaptoethanol). An amount of 30 μg of aliquots from C57BL/10
and treated and untreated-mdx STN, DIA, and BB muscles was loaded
onto 8%–15% SDS-polyacrylamide gels. Proteins were transferred
from the gels to a nitrocellulose membrane using a submersion
electrotransfer apparatus (Bio-Rad Laboratories, Hercules, California,
USA). Membranes were incubated with the primary antibodies,
followed by peroxidase-conjugated secondary antibodies and by
development with SuperSignal West Pico Chemiluminescent Substrate
kit (Pierce Biotechnology, Rockford, Illinois, USA). To control for protein
loading, western blot transfer and nonspeciﬁc changes in protein levels,
the blots were stripped and re-probed for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The luminescent signal from Western blot
bands was captured by a G:Box iChemi camera (Syngene, Cambridge,
UK) and band intensities were quantiﬁed using the analysis software
provided by the manufacturer (Gene Tools Version 4.01, Syngene,
Cambridge, UK).
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TNF-α (rabbit anti-mouse polyclonal; Millipore, CA, USA), and 2)
GAPDH (rabbit polyclonal; Santa Cruz Biotechnology, Santa Cruz,
California, USA). The corresponding secondary antibody used for
Western blotting was peroxidase-labeled afﬁnity-puriﬁed rabbit IgG
antibody (H+L) (KPL, Gaithersburg, Maryland, USA).
2.7. Statistical analysis
All data are expressed as means±standard deviation (SD).
Statistical analysis for direct comparison between means of two groups
was performed by the Student t-test and ANOVAwas used for multiple
statistical comparisons between groups. Pb0.05 was considered
statistically signiﬁcant.
3. Results
At the beginning of treatment (14 days of age), body mass was
comparable among the groups studied (6.8±0.5 g in untreated-mdx
and 7.2±0.7 g in EPA-mdx). There was a signiﬁcant increase (about
45–50% compared to initial body mass) in body mass over time in both
untreated- (10.0±1.2 g; p=0.004 compared to initial body mass,
Student t-test) and EPA-treated (11.3±2.0 g; p=0.02 compared to
initial body mass, Student t-test) mdx. Thus, EPA treatment did not
interfere with the growth rate of youngmdxmice.
3.1. Histopathology
The histological appearance of amuscle fromnormal C57BL/10mice
and from EPA-treated and untreated-mdx mice is shown in Fig. 1. In
normalmice,muscle ﬁberswith homogeneous diameter and peripheral
nuclei locateddirectly below the sarcolemmawere observed. In themdx
mice, the inﬂammatory area was deﬁned by areas containing
conspicuous inﬂammatory cells densely packed among regenerated
muscle ﬁbers and muscle ﬁbers under degeneration. Fully regenerated
muscle ﬁbers, characterized by central nucleation and an apparent
normal diameter, predominated outside the inﬂammatory area. Groups
of F4/80-expressing cells were present in all untreated-mdx musclesFig. 1. Histological appearance of control C57BL/10, untreated and EPA-treatedmdxmice. Upp
nuclei (asterisk) in control and in EPA-treatedmuscles. In untreated-mdx, a representative inﬂa
nucleatedﬁber (arrow). Bottomrow: representative areas ofbicepsbraquiimuscle labeledwith
60 μm.(shown only in BB) and were decreased in the EPA-treated mdx mice
(Fig. 1).
3.2. Analysis of myonecrosis: Evans blue dye, central nucleated ﬁbers and
CK
EPA caused a signiﬁcant decrease in Evans blue dye staining,
indicative of sarcolemma leakiness and myonecrosis, with a concom-
itant increase in ﬁbers with peripheral nuclei, in all muscles studied
(Table 1). There was a reduction of central nucleated ﬁbers in the
EPA-treated muscles, with a signiﬁcant decreased seen only in STN
muscle (Table 1), possibly due to the higher levels of these ﬁbers in the
untreated-STN in comparison to BB andDIA. CK levelswere signiﬁcantly
decreased by EPA compared to untreated-mdx mice (838±347 U/L
in EPA-treated vs 1208±376 U/L in untreated-mdx; p=0.04, Student's
t-test).
3.3. Analysis of inﬂammation: inﬂammatory area and TNF-α levels
Quantitative data about the inﬂammatory area is shown in Fig. 2.
While untreated DIA presented the lowest inﬂammatory area (13%),
limb and STNmuscles showed the highest values, with about 65% (BB)
to 100% (STN) increase in comparison to DIA. EPA decreased the
inﬂammatory area in all muscles studied (Fig. 2).
The levels of TNF-α in dystrophic STN, DIA and BB were
signiﬁcantly higher in untreated-mdx muscles in comparison to
normal C57BL/10 mice (Fig. 3). The highest level of TNF-α was
observed in STN, followed by BB and DIA (Fig. 3). EPA led to a
signiﬁcant reduction in the levels of TNF-α in all muscles (about 50%
reduction in STN and BB and 25% in DIA; Fig. 3).
4. Discussion
EPA is a 20-carbon omega (n)-3 polyunsaturated fatty acid with
anti-inﬂammatory properties, which is synthesized from ingested
alpha-linolenic acid or is consumed in ﬁsh and ﬁsh oil (Arterburn
et al., 2006). The present study demonstrated that treatment of mdx
mice with EPA resulted in a decrease of serum CK levels and Evans
blue dye-positive ﬁbers and a concomitant increase in peripheraler row: sternomastoid muscle stained with hematoxilin–eosin. Fiber with peripheral cell
mmatory area is indicated by the outline, with necrotic ﬁbers (arrow). In EPA-mdx, central
F4/80antibody.Groupsof F4/80-expressingcells are seen inuntreated-mdxmice. Scalebar:
Table 1
Effects of EPA treatment on the percentage of muscle ﬁbers with peripheral cell nuclei (peripheral nuclei), centrally located nuclei (central nuclei), and ﬁbers stained with Evans blue
dye (EBD).
Total number of ﬁbers Peripheral nuclei (%) Central nuclei (%) EBD (%)
STN Untreated 966±52.27 50.0±4.5 34.3±2.3 15.6±2.6
Treated 882±84.22 70.5±5.5⁎pb0.001 25.2±5.3⁎ pb0.001 4.2±2.2⁎ pb0.001
DIA Untreated 1250±90.5 73.4±6.6 10.2±3.5 16.3±7.0
Treated 1320±94.2 86.7±4.3⁎ pb0.001 8.0±2.7 5.2±2.7⁎ p=0.004
BB Untreated 961±88.6 71.7±8.3 18.6±7.3 9.3±3.6
Treated 1183±109.35 83.3±3.0⁎ p=0.03 13.8±3.0 4.2±1.8⁎ p=0.01
Values are expressed as the percentage (mean±SD; n=5 mice) of the total number of ﬁbers of the sternomastoid (STN), diaphragm (DIA) and biceps brachii (BB) muscles.
⁎ Signiﬁcantly different from untreated-mdx mice within the same muscle group (Student t-test).
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together, these results show that EPA treatment exerts a protective
effect on myoﬁber breakdown in limb (BB) and axial (STN and DIA)
muscles of young mdx mice.
In the present study, the dose of EPA used (300 mg/kg) seems to be
higher thanmightbeexpected tohumanpatients,where a1000 mg/day
of EPA is usually recommended. However, care must be taken to
extrapolate dose from mice to humans, especially if we consider
differences in metabolism, in the duration of treatment and in the
progression of dystrophy. In an experimental cachexia model in rats, it
was observed that EPA inhibited tumor growth and bodyweight loss in
a dose-dependent manner, with optimal effects seen at higher doses
(1.25–2.5 g/kg bodyweight) than that used here. Toxicitywas observed
at a dose of 5 g/kg (Tisdale and Dhesi, 1990). In patients with advanced
pancreatic cancer, the oral intake of a nutritional supplement enriched
with 1.09 g of EPA, twice a day, attenuated the progression of cachexia
(Barber et al., 1999). Thus, considering that DMD patients may need a
long therapy, the lower recommended dose should be more appropri-
ate, but clinical experiments are necessary to properly address this
question.
Inﬂammation is a hallmark of dystrophic muscles and strongly
contributes to the progression of the disease (Chen et al., 2000; PorterFig. 2. Quantitation of inﬂammatory area in sternomastoid (STN), diaphragm (DIA) and
biceps brachii (BB) muscles from untreated (n=7) and EPA-treated (n=7) mdxmice.
The inﬂammatory area is represented as a percentage of the total muscle area. *Means
signiﬁcantly different from untreated-mdx. Student t-test. Error bars, SD.et al., 2002). Although COX-2-derived eicosanoids do not seem to
contribute to the progression of dystrophic disease (Pierno et al.,
2007), the inhibitory action of EPA on arachidonic acid metabolism
through the 5-lipoxygenase and cyclooxygenase enzymatic pathways,
suppressing the production of n-6 eicosanoid inﬂammatorymediators
(James et al., 2000; Calder, 2008), may explain at least in part the
reduced muscle damage seen in dystrophic mdx muscle ﬁbers.
In dystrophic muscles, mast cells rapidly accumulate once muscle
damagebeginsandmacrophages are predominantbetween12 h to24 h
after the injury (Radley and Grounds, 2006). Distinct macrophages
populations may inﬂuence the course of mdx dystrophy (Villalta et al.,
2009) and both,mast cells andmacrophages, produce proinﬂammatory
cytokines such as TNF-α. We observed F4/80-expressing cells in all
dystrophic muscles studied, at this early stage of dystrophy, further
supporting the primary roles ofmacrophages inmdx dystrophy (Villalta
et al., 2009; Wehling et al., 2001). It is well known that inhibition of
TNF-α production protects dystrophin-deﬁcient mdx ﬁbers against
muscledegeneration (Radley andGrounds, 2006;Waters et al., 2010). In
the present study, EPA reduced immunoﬂuorescence labeling of
macrophages, reduced signiﬁcantly TNF-α levels in all muscles studied
and amelioratedmyonecrosis,ﬁndings indicating a role ofmacrophages
and TNF-α in the early stages of disease in muscles that are affected
differently by the lack of dystrophin. The present ﬁndings are in
agreement with previous studies showing that EPA is able to decrease
TNF-α levels by inhibiting its production by macrophages (Babcock
et al., 2002), and also to reduce serumTNF-α levels in exercised humans
(Bloomer et al., 2009).
The mechanisms whereby EPA exerts its anti-TNF effects are
poorly understood. One possibility is that EPA decreases transcription
of the TNF-α gene by reducing the translocation of NF-kB, a
proinﬂammatory transcription factor (Joussen et al., 2002), from the
cytoplasm to the nucleus (Lo et al., 1999; Singer et al., 2008).
Disturbances in NF-kB signaling have been described in mdx mice
(Acharyya et al., 2007) and in DMD (Monici et al., 2003). EPA may
prevent the damaging effects of TNF-α on muscle ﬁbers as
demonstrated in in vitro studies on skeletal muscle differentiation
(Magee et al., 2008). Additionally, EPA may improve dystrophic
muscle regeneration, since it was demonstrated that this omega-3
fatty acid regulates myogenic regulatory factors and attenuates
muscle wasting by preventing muscle protein degradation (Castillero
et al., 2009).
In conclusion, the present study demonstrated that the administra-
tion of highly puriﬁed EPA to dystrophic mdx mice decreases
inﬂammation, myonecrosis and TNF-α levels in different dystrophin-
deﬁcient skeletal muscles. EPA has been tested in several clinical trials
for different diseases and its effects in reducing the risk of cardiac death
are well documented (Nestel, 2000; Harper et al., 2006). Although
further studies are necessary to better understand the mechanisms
whereby EPAmodulates immunoinﬂammatory pathways in dystrophic
muscle, thepresent results suggest that therapeutic strategies using EPA
as a supplemental or primary therapy may ameliorate dystrophic
muscle pathology.
Fig. 3. Immunoblot analysis of tumor necrosis factor (TNF)-alpha levels in crude extracts of sternomastoid (STN), diaphragm (DIA), and biceps brachii (BB) muscles from control
C57BL/10 (n=8), and from untreated (n=8) and EPA-treated (n=8)mdxmice. A. Western blot. B. Quantitation shows higher levels of TNF-α in dystrophic muscles compared to
normal mice (untreated×C57BL/10). EPA led to a signiﬁcant reduction in TNF-α levels in all muscles. Levels of TNF-α expressed in arbitrary units normalized to the levels of GAPDH,
which was used as a loading control. Signiﬁcantly different from EPA-mdx (a), from C57BL/10 (b) and from untreated-mdx (c), ANOVA. Error bars, SD.
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